

A Teaching Affiliate of Harvard Medical School

## "A Review of Cancer Immunotherapy Toxicity in Practice & Clinical Trials"

Kerry Reynolds, MD Clinical Director, Inpatient Oncology Units Director, Severe Immunotherapy Complications Service Massachusetts General Hospital, Boston, MA





#### No relevant financial relationships to disclose



- Review the terminology of grading toxicities for Immune Related Adverse Events (irAEs)
- Provide an overview of the evaluation of the oncology patient who may have an irAE related to immunotherapy treatment
- Review the steps in management of patients with irAEs that are hospitalized (e.g. myocarditis, pneumonitis)



## **Questions to Contemplate**

- How many patients are expected to have a serious immune-related adverse event (irAE) this year in the US alone? (300, 3,000, 10,000, well over 30,000)
- If a patient has one irAE, are they at risk for another? Y/N
- Are all irAE's treated with steroids? Y/N
- Do some irAE's require different doses of steroids? Y/N
- What is the most common organ system involved?
- What are the two most fatal toxicities?




#### **FDA Approvals for Immune Checkpoint Inhibitors**

October J, 2015 Nive for CHL       May 16, 2016 Nive for CHL       February 12, 2017 Nive for CHL       February 12, 2017 Dury for unchelial carcinomal       February 15, 2018 Dury for unchelial carcinomal       February 15, 2018 Dury for unchelial carcinomal       February 15, 2018 Dury for unchelial carcinomal       February 15, 2018 Pembro for KSCL       January 6, 2020 Pembro for kight - risk Nive for NSCLC       January 6, 2020 Pembro for NSCLC         October 2, 2015 Pembro for NSCLC       March 14, 2017 Pembro for SCCHN       March 14, 2017 Pembro for cervical carcinoma       March 14, 2018 Pembro for cervical carcinoma       March 13, 2019 March 13, 2019 March 14, 2017 Pembro for SCCHN       March 14, 2017 Pembro for cervical carcinoma       March 13, 2019 March 14, 2016 March 14, 2017 Pembro for SCCHN       March 14, 2017 Pembro for cervical carcinoma       March 14, 2017 March 14, 2018 Pembro for cervical carcinoma       March 14, 2017 March 14, 2019 March 14, 2019 March 14, 2010 March 14, 20	2015	2016	2017	2018	2019	2020	2021
September 22, 2017       September 12, 2014       July 27, 2021         Pembro for gastric cancer       September 17, 2019       June 29, 2020         Nivo for metastatic melanoma       June 29, 2020       August 17, 2021         March 25, 2011       September 4, 2014       June 29, 2020       August 19, 2021         March 25, 2011       September 4, 2014       June 29, 2020       August 19, 2021         December 3, 2019       June 29, 2020       August 19, 2021       August 19, 2021         March 25, 2011       September 4, 2014       June 29, 2020       August 19, 2021         December 3, 2019       June 29, 2020       June 29, 2020       August 19, 2021         March 25, 2011       September 4, 2014       Pembro for colorectal cancer       June 30, 2020         More 123, 2011       December 23, 2014       Nivo for unresectable or metastatic melanoma       June 29, 2020       October 13, 2021         December 23, 2014       Pembro for unresectable or metastatic melanoma       October 13, 2021       November 17, 2021         December 23, 2014       Nivo for unresectable or metastatic melanoma       December 23, 2014       November 17, 2021         Nivo for unresectable or metastatic melanoma       December 23, 2014       November 17, 2021         Nivo for unresectable or metastatic melanoma       December 23, 2014	2011 March 25, 2011 March 25, 2011 Pembro for wsclct October 2, 2015 Pembro for NSCLC October 29, 2015 Nivo for second line November 13, 2015 Nivo for second line Squamous NSCLC December 13, 2015 Nivo for RCC December 13, 2015 Unit of the second line Squamous NSCLC December 13, 2015 Pembro for unresectable melanoma	4,2014 elelanoma 3,2014 ttable or the for the	February 1, 2017 Nivo for unothelial carcinoma March 14, 2017 Pembro for cHL Arril 30, 2017 Durva for unothelial carcinoma May 9, 2017 Avelu for MrCC May 9, 2017 Pembro for non- squamous NSCLC May 12, 2017 Pembro for non- squamous NSCLC May 12, 2017 Pembro for colorectal cancer May 22, 2017 Pembro for colorectal cancer September 22, 2017 Pembro for gastric cancer September 22, 2017	February 16, 2018 Durva for unresectable NSCLC April 16, 2018 Nivo + tpilumab for RCC June 12, 2018 Pembro for cervical cancer June 13, 2018 Pembro for PMBCL July 10, 2018 Nivo for PMBCL August 17, 2018 Nivo for SCLC August 20, 2018 Pembro for Platinum in 1st line, NSCLC November 9, 2018 Pembro 1, 2018 Attro-t Beva + Taxol + Carbo for NSq NSCLC December 19, 2018	February 15, 2019 Pembro in adjuvant melanoma March 8, 2019 Atezo + Nab-Taxolfor TNBC March 18, 2019 Atezo + Carbo/Etop in SCLC April 11, 2019 Pembro for stage 3 NSCLC April 19, 2019 Pembro for stage 3 NSCLC May 14, 2019 Pembro for metastatic HNSCC June 10, 2019 Pembro for metastatic HNSCC June 10, 2019 Pembro for metastatic HNSCC June 17, 2019 Pembro for esophageal September 17, 2019 Pembro for endometrial carcinoma September 27, 2019 Pembro F and constrained Carcinoma	January 8, 2020 Pembro for high - risk bladder cancer Nivo + lpi for HCC Durva + Etoposide + Carbo or Cisplatin for ES-SCLC Nivo + lpi for NSCLC May 18, 2020 Nivo + lpi for NSCLC May 28, 2020 Nivo + pi + Chemo for NSCLC May 29, 2020 Atezo + Beva for Nivo for sophageal squamous cell June 10, 2020 Nivo for colapageal squamous cell June 16, 2020 Pembro for cutaneous carcinoma June 29, 2020 Pembro for cutaneous carcinoma June 29, 2020 Pembro for cutaneous carcinoma June 29, 2020 Pembro for cutaneous carcinoma June 29, 2020 Pembro for cutaneous carcinoma June 30, 2020 Atezo + Cobimetinib Vemuratenib in melanoma October 2, 2020 Nivo + lpi for	January 22, 2021 Nivo + Chemo for RCC February 2, 2021 Cemi for advanced basal cell carcinoma February 22, 2021 Cemi for NSCL March 22, 2021 Pembro + Chemo for esophageal carcinoma April 16, 2021 Nivo for endometrial cancer May 5, 2021 Dostar for endometrial cancer May 5, 2021 Pembro + Chemo for gastric cancer May 20, 2021 Nivo for esophageal July 27, 2021 Pembro + Chemo for cancer July 27, 2021 Pembro for breast cancer August 17, 2021 Nivo for urothelial cancer Cotober 13, 2021 Pembro - themo for cenvicat cancer Cotober 13, 2021 Pembro + Scano for cenvicat cancer Cotober 13, 2021 October 15, 2021 Atezo for NSCLC



advanced breast cancer

## Immune-Related AEs (irAEs)



### **Grading Criteria for Adverse Events**

Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5				
Gastrointestinal Toxicity									
Diarrhea	Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline	Increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline	Increase of >=7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL	Life-threatening	Death				



#### **Common Terminology Criteria for Adverse Events (CTCAE)**

### **<u>Grading Toxicity</u>**

#### Common Terminology Criteria for Adverse Events (CTCAE)

Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)

U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute

- <u>Grade 1:</u> Mild, asymptomatic, no intervention required
- <u>Grade 2</u>: Moderate, local or non-invasive intervention required
- <u>Grade 3:</u> Severe or medically significant, but not lifethreatening.
- <u>Grade 4:</u> Life-threatening consequences; urgent intervention required
- Grade 5: Death related to AE



#### **Adverse Events Frequency**


	ANY TOXICITY	SEVERE G3-4	STOPPED Tx	DEAT
PD-1	74%	14%	6%	<b>6</b> %
CTLA-4	89%	34%	21%	1.3%
COMBO ICI+ICI	90%	55%	38%	1.23%
COMBO ICI+CHEMO	89%	46%	13%	1.1%

Arnaud-Coffin, IJC, 2019

Wang, JAMA Onc, 2020




#### **Proposed Mechanisms**





Lee, Curr Card Reports, 2021, In Press

#### **Massachusetts General Hospital**



#### 11 Molina, Zubiri, et al, Oncologist, 2020

#### **GYN ICI Patients at MGH**

GYN								
ICI REGI 2015	2016	2017	2018	2019	2020	2021	TO	TALS
ipilimum	0	0	0	0	0	0	0	0
nivoluma	0	12	32	20	11	11	10	96
ipilimum	0	1	2	2	6	6	5	22
pembroli:	2	16	27	22	34	55	48	204
atezolizu	0	3	1	1	1	1	1	8
avelumab	0	5	17	12	7	6	3	50
durvalum	0	0	0	0	0	9	1	10
nivoluma	0	0	0	0	0	0	0	0
TOTALS	2	37	79	57	59	88	68	390




## **SUMMARY OF INTRO SLIDES**

- Immune Checkpoint Inhibitors Are Now Standard of Care
- Success of Single Agent ICI Led To Combination Approvals
- Subset of Patients Experience Durable, Long Term Response
- Be Aware Of The Unique "Autoimmune" Toxicity Profile
- irAEs Often Within First 3-6 Months
  - Unlike chemotherapy they can last for weeks/months
  - Can occur after ICI discontinuation
- Mechanism is Not Well Understood
- irAEs are Typically Grade 1/2 but Severe irAEs Can Be Fatal
- Multi-disciplinary Care Team Implementation is Key



## Case, 47 Year Old Man



- 4/2016: Dx: Liver biopsy returned with malignant cells consistent with cholangiocarcinoma.
- 5/2016: Gemcitabine/Cisplatin
- 11/2016: Progressive disease, changed to Nivolumab + TAK-659
- 1/2017: Hypoxia/infiltrates/EF 45%, Myocarditis related to Nivolumab
- 2/2017: Slight decrease in liver lesion
- 3/2017: EF 68%, New Dx: Hepatitis related to Nivolumab
- 6/2017: Anemia/thrombocytopenia
- 2017: Extensive compression fractures due to osteoporosis from chronic high dose steroids, needed Kyphoplasty
- Pass away Refractory Toxicity from Immune Checkpoint Inhibitors



#### Many Questions, Few Answers

SIC

**Service** 

Can we define these events and develop **best practices** to manage the atypical presentations of toxicity?

Can we uncover **predictors** for the development of severe toxicity?

Or **biomarkers** to indicate if a pt will have an uncomplicated course or one like this patient?

What is the **underlying pathophysiology** of these new disease? How can that inform clinical trials for **treatment** of toxicity.

Can this be a **window into understanding** early mechanisms of immune regulation (*irAE/autoimmune disease*)

Can we **uncover novel drug targets** that have immunosuppressive potential but preserve tumor

#### **Guidelines – ASCO, NCCN**



NCCN Guidelines, May, 2021 Brahmer, SITC Guidelines, JITC, June 25, 2021 Haanen, Annals of Oncology, 2017 (ESMO) Brahmer, Journal of Clinical Oncology, February, 2018



#### Focus on SITC Guidelines

Position article and guidelines

#### Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R Brahmer,<sup>1</sup> Hamzah Abu-Sbeih,<sup>2</sup> Paolo Antonio Ascierto <sup>(0)</sup>, <sup>3</sup> Jill Brufsky,<sup>4</sup> Laura C Cappelli,<sup>5</sup> Frank B Cortazar,<sup>6,7</sup> David E Gerber,<sup>8</sup> Lamya Hamad,<sup>9</sup> Eric Hansen,<sup>10</sup> Douglas B Johnson,<sup>11</sup> Mario E Lacouture,<sup>12</sup> Gregory A Masters,<sup>13</sup> Jarushka Naidoo,<sup>1,14</sup> Michele Nanni,<sup>10</sup> Miguel-Angel Perales,<sup>12</sup> Igor Puzanov,<sup>10</sup> Bianca D Santomasso,<sup>15</sup> Satish P Shanbhag,<sup>5,16</sup> Rajeev Sharma,<sup>10</sup> Dimitra Skondra,<sup>17</sup> Jeffrey A Sosman,<sup>18</sup> Michelle Turner,<sup>1</sup> Marc S Ernstoff <sup>(5)</sup> <sup>19</sup>


#### ABSTRACT

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for a wide variety of cancer types. A study of ICI usage estimated that in 2018, 44% of patients with metastatic solid or hematological tumors in the US were eligible for treatment with ICIs.<sup>2</sup> ICIs are also a focus of active drug development, and a number of ongoing trials are evaluating novel antibodies or testing



## **Basic Toxicity Management Summary**


- MILD: Treat symptomatically
- PERSISTENT MILD or MODERATE: Oral corticosteroids (i.e. prednisone 1mg/kg/qd)
- PROGRESSIVE, SEVERE, OR LIFE-THREATENING:
  - Hospitalize & begin high dose IV steroids (i.e. methylprednisolone 1 mg/kg qd or bid)
  - If steroid refractory, consider starting immunosuppressive meds (such as mycophenolate mofetil in the case of hepatitis or infliximab in the case of colitis)



Nature Reviews | Clinical Oncology



#### **Managing Refractory Cases**



#### Zhang, JACC, Cardiooncology, 2021 Frayberg, Curr Onc Reports, 2021

MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER

### **Hepatitis**


- Hold immunotherapy > grade 2 (3-5X ULN) transaminases
  - Stop any hepatotoxic medications (Tylenol, herbal supplements, alcohol)
  - Rule out viral (Hep A/B/C/E, CMV, EBV, HSV, VZV, HIV) etiology
  - Rule out (other) drug-induced process
  - Look for evidence of disease/alternative diagnosis
    - Imaging US, consider CT/liver MRI depending on clinical scenario
    - Consider ceruloplasmin, alpha-1-antitrypsin, ferritin, ANA titer, mitochondrial Ab M2, smooth muscule Ab, LKM type 1, tissue transglutaminase IgA and IgG, TSH, iron, transferrin
- - Management:
  - Grade 2 prednisone .5-1 mg/kg/day
  - Grade 3 prednisone 1-2 mg/kg/day
  - If no improvement after 3 days, add Cellcept



## **Generalists/Specialists are All Critical**

- Cardiac Immediate Cardiology consultation
- Grade 1 pancreatitis Consider GI referral
- Grade 2 colitis Consider Gl consultation
- Mild eye changes Refer to Ophthalmology
- Myasthenia Gravis, GBS Refer to Neurology
- Grade 2 Nephrology consultation
- Grade 2 pneumonitis Pulmonary consultation
- Moderate myositis Rheumatology or neurology consultation
- Hyperglycemia < 200 Consider Endocrine consultation, > 200 endocrine consultation
- Primary AI Endocrine consultation
- Hypophysitis Consider Endocrine consultation
- Grade 3 LFTs Hepatology consultation
- Grade 3,4 Rash Dermatology consultation, SJS/TENS dermatology, urology, ophthalmology
- 21

#### Immunotherapy Toxicity Service



For more information: https://www.massg eneral.org/cancercenter/treatmentsandservices/severeimmunotherapycomplications/

Represents Clinical Research


Represents Translational Research






## Immunotherapy Toxicity Service





#### **SIC Service**






## **SIC Service Implementation**

#### Zubiri, JITC, 2021, In Press

	Pre-SIC <sup>a</sup>	Post-SIC <sup>b</sup>	
	( <i>n</i> = 127	( <i>n</i> = 122	
Characteristic	patients)	patients)	P Value
Age, mean (SD), y	62.6 (13.9)	64.6 (11.1)	0.216
Female Sex	44 (34.7%)	55 (45.1%)	0.093
Cancer Type			
Melanoma	48 (37.8%)	31 (25.4%)	
Thoracic	35 (27.6%)	38 (31.2%)	
Gastrointestinal	14 (11.0%)	26. (21.3%)	
Genitourinary	8 (6.3%)	9 (7.4%)	
Hematologic	3 (2.4%)	7 (5.7%)	0.156
Gynecologic	5 (3.9%)	3 (2.5%)	0.150
Head and Neck	5 (3.9%)	2 (1.6%)	
Neurologic	3 (2.4%)	4 (3.3%)	
Breast	5 (3.9%)	2 (1.6%)	
Sarcoma	1 (0.8%)	0	
ICI Type			
CTLA4	9 (7.1%)	3 (2.5%)	
PD1	84 (66.1%)	92 (75.4%)	0.147
PDL1	8 (6.3%)	10 (8.2%)	0.147
CTLA4 + PD1	26 (20.5%)	17 (13.9%)	
irAE Type			
Allergy	3 (2.4%)	1 (0.8%)	
Cardiac	9 (7.1%)	11 (9.0%)	
Dermatologic	9 (7.1%)	3 (2.5%)	
Endocrine	15 (11.8%)	13 (10.7%)	
Gastrointestinal	28 (22.1%)	20 (16.4%)	
Hepatic	20 (15.8%)	23 (18.9%)	0.311
Hematologic	4 (3.2%)	2 (1.6%)	
Neurologic	10 (7.9%)	14 (11.5%)	
Pulmonary	26 (20.5%)	26 (21.3%)	
Renal	1 (0.8%)	7 (5.7%)	
Rheumatologic	2 (1.6%)	2 (1.6%)	

#### **Decreased Readmission Rates**

	Pre-SIC <sup>a</sup>	Post-SIC <sup>b</sup>		
	( <i>n</i> = 166	( <i>n</i> = 149	Coefficient / OR	
Outcome	admits)	admits)	(95% CI)°	P Value
Length of stay, median (IQR), days	5.5 (3-11)	5 (3-9)	-1.7 (-3.56-0.19) <sup>d</sup>	0.078
Discharged on corticosteroidse	121 (75.6%)	96 (69.1%)	0.60 (0.33-1.10)f	0.101
Use of non-steroidal immunosuppression	24 (14.5%)	18 (12.1%)	0.87 (0.43-1.77) <sup>f</sup>	0.702
ICI discontinuation for irAE <sup>®</sup>	74 (66.1%)	61 (67.0%)	1.04 (0.55-1.98) <sup>f</sup>	0.897
Died during irAE admission	11 (6.6%)	13 (8.7%)	1.46 (0.60-3.55) <sup>f</sup>	0.398
IrAE readmission	43 (25.9)	22 (14.8)	0.46 (0.22-0.95) <sup>h</sup>	0.036
Length of stay of irAE readmission,				
median (IQR), days	7 (3-16)	6 (3-10)	-8.08 (-16.03, -0.14)d	0.046



## **SUMMARY SLIDE FOR SECTION 2**

- Serious irAE can involve a wide range of organ systems
- There is recognition that all generalists and diseasespecific subspecialists are essential in the management of irAEs
- It is important to develop expertise to recognize irAEs and to educate all types of providers (MDs, NPs, RNs, residents, patients)
- Steroids are the mainstay of treatment but:
  - Higher doses are required in myocarditis, encephalitis
  - Steroids are not required for endocrinopathies




### **Treatment – How Much? When?**

▦▦▦▦▦ 23 Sites

# 16.7%




Low dose < 60 mg/d methylpred





Intermediate dose < 60-500 mg/d



38.1%

24-72 Hrs

High dose < 501-1000 mg/d

> 72 Hrs

MACE: Major adverse cardiac arrest/shock, or sig heart block

High Dose Steroid Group – 22% MACE Int Dose Steroid Group - 54.6% MACE Low Dose Steroid Group 61,9% MACE



events: CV death, cardiac requiring pacemaker


CANCER CENTER

#### High Dose Steroids for the Win

#### Early Steroids for the Win



## **Informing Treatment Guidelines**



Clearly an inverse relationship between initial dose of corticosteroids and MACE - High dose was associated with a 73% lower risk of MACE (HR .27)

# Earlier the better! (HR for < 24 hrs, 0.03, HR for 24-72 0.3)



Zhang, Circulation, 2020



- 51 yo male with stage IIIB melanoma on adjuvant nivolumab (cycle 21 completed 7/16/18) presenting with AKI
  - 7/20/18: developed increasing fatigue, chills and night sweats
  - 7/27/18 clinic visit: creatinine 1.69 from baseline 1
    - Given 2L NS in office with no change in creatinine on re-check later that day
    - Sent home with follow-up in 4 days
  - 7/31/18 clinic visit: creatinine 2.90
    - Admitted to hospital



## **Oncologic History**

- Stage IIIB melanoma
  - 02/2013: melanoma in situ on right neck, resected
  - 05/2017: left thigh melanoma; wide excision with sentinel lymph node biopsy performed, SLN positive; PET-CT demonstrated left inguinal LN FDG uptake proximal to the surgical site
  - 07/17/17: completion dissection performed, 2/11 LNs positive, NED afterwards (stage IIIA or IIIB)
  - 10/6/17: started adjuvant nivolumab 240 mg (3mg/kg) q2wk as part of clinical trial
  - Serial scans afterwards show no evidence of disease
  - Underwent 21 cycles of nivolumab from 10/2017 to 07/2018
    - No IrAEs with treatment



## **Other medical history**

- Medical history
  - DVT: diagnosed in 07/2017 following lymph node dissection, previously on Eliquis; discontinued iso no evidence of disease
  - GERD
- Home medications:
  - **Omeprazole** 20 mg daily
  - No prior steroid or other immunosuppressant use
  - No recent antibiotic use, minimal NSAID use (one dose in last week)
- Allergies
  - NKDA



### Physical Exam – Unremarkable, Labs:

BMP		LFTs		Extended	labs
Na	137	ALT	17	Ca	9.2
К	3.9	AST	17	LDH	<b>4</b> 215
CI	95	Alk phos	65	Sosm	293
Bicarb	25	Tbili	0.4	TSH	1.91
BUN	▲ 34	Alb	4.0		
Cr	<b>2.83</b>	Prot	7.6		
Gluc	106				



## **Diagnostics**

#### CBC

#### WBC 9.8

- 74% NP
- 7% lymph
- 11.7% monos
- 6.3% Eos
- 0.3% basos

**•** 12.4

**v** 37.8

322

Hgb

- Hct
- Plt

# Immunologic studies

• C3 160

45

neg

neg

- C4
- ANA
  - dsDNA
- ANCA neg
- U/A negative
- Mild increase in protein

#### Micro

- HBV serologies neg
- HCV neg
- HIV neg
- BCx x 2 neg
- UCx neg CT Abdomen/Pelvis (7/31/18):

"The kidneys are edematous with apparent enlargement relative to prior CT with new perinephric edema. No hydronephrosis, stones, or solid mass lesions"

CANCER CENTER

34



#### Core biopsy (performed 8/1/18, HD 2):

- Severe acute tubulointerstitial nephritis:
  - "Interstitium contains a severe inflammatory infiltrate composed mainly of lymphocytes with admixed eosinophils and few plasma cells and neutrophils, involving approximately 70% of the cortical area and associated with moderate to severe tubulitis (more than 10 cells per tubular cross section)."
- No significant fibrosis or irreversible damage
- No glomerular pathology




#### **Treatment**

- Omeprazole discontinued, ranitidine started
- 8/2: Solumedrol 500 mg x 1 given
- 8/2: prednisone taper started (59 days, 8/2 10/2)
  - 7 days prednisone 60 daily (8/2 8/8)
  - 7 days prednisone 40 daily (8/9 8/15)
  - 7 days prednisone 30 daily (8/16 8/22)
  - 7 days prednisone 20 daily (8/23 8/29)
  - 14 days prednisone 15 daily (8/30 9/12)
  - 14 days prednisone 10 daily (9/13 9/26)
  - 5 mg prednisone daily indefinitely (9/27 10/2)
- Total steroid duration: 60 days
  - 1 day IV steroids (500 mg IV solumedrol x 1)
  - 59 days PO steroids









## AKI outcomes


- Improved to baseline within 1 month
  - Rapid improvement in AKI after steroid initiation
  - Creatinine halved by day 9 of treatment
  - Creatinine returned to baseline at day 20 of treatment
- Discharged home on hospital day 4







What is the frequency & etiology of AKI and what are its risk factors in patients on checkpoint inhibitors?



**Conclusions:** AKI is common in patients receiving checkpoint inhibitors, and the causes are heterogeneous. Proton pump inhibitor therapy is a risk factor for sustained AKI.

Harish Seethapathy, Sophia Zhao, Donald Chute, Leyre Zubiri, et al. *The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.* CJASN doi: 10.2215/CJN.00990119. Visual Abstract by Pablo Garcia, MD



#### Seethapathy et al, CJASN, 2019

## Do we need a long taper of steroids?

- Permanently discontinue AIN-associated medications (PPI, allopurinol, NSAIDS, antibiotics).
- Temporarily hold ICI.
- Begin prednisone 1mg/kg/day In hospitalized patients, consider 1-3 days of intravenous methylprednisolone. Repeat creatinine in 5-7 days provided creatinine is improving by ≥25%.
- Continue rapid taper Rapid corticosteroid taper: 40mg x 3 days, 30mg x 3 days, 20mg x 3 days, 10mg daily.
- Repeat creatinine every 7 days and continue taper as long as creatinine continues to decline.
- If creatinine rises, restart 60mg day and taper over 4-6 weeks.






# **Clinical Outcomes**

	Rapid taper	Standard of care		
	n=13	n=14		
Corticosteroid treatment, count (%) or median (IQR)				
Received intravenous pulse methylprednisolone	3 (23%)	6 (43%)		
Grams of methylprednisolone	0.75 (0.2–1.0)	0.65 (0.13–1)		
Initial daily oral prednisone dose, mg	60 (60–60)	60 (6–60)		
Median days at initial oral prednisone dose*	7 (3–7)	7 (6–8)		
Median days until≤10 mg of prednisone	20 (15–25)	38 (30–58)		
Received second-line immunosuppression	0	0		
Renal recovery (defined by creatinine<1.5 fold baseline)				
Renal recovery within 30 days	11 (85%)	6 (46%)		
Best creatinine (mg/dL) within 30 days, median (IQR)	1.31 (1.13–1.45)	1.49 (1.29–1.62)		
Renal recovery within 60 days	11 (85%)	9 (64%)		
Best creatinine within 60 days	1.18 (1.02–1.34)	1.35 (1.29–1.49)		
Corticosteroid refractory nephritis† at 90 days	1 (8%)	4 (29%)		
Steroid re-initiated or re-escalated prior to ICI-rechallenge	2 (15%)	2 (14%)		
Median time to renal recovery, days (IQR)	11 (7–18)	36 (20–100)		
Rechallenge with ICI				
Rechallenged with ICI	7 (54%)	8 (57%)		
Median days until rechallenge (IQR)	26 (15–182)	135 (53–290)		
Relapse of ICI-induced nephritis after ICI rechallenge	1 (14%)	1 (13%)		
Relapse within another severe irAE after rechallenge‡	2 (29%)	3 (38%)		
Receiving prednisone at rechallenge	6 (86%)	7 (88%)	ASSACHUSETTS	
Median dose of oral prednisone at rechallenge	10 (3.8–10)	7.5 (3.8–10)	NERAL HOSPITA	
Experienced clinical benefit from ICI rechallenge	4 (57%)	4 (50%)	ANCER CEN	

## Patients on Rapid Taper Did Well










A Teaching Affiliate of Harvard Medical School

# Cases



### Fatigue (21-36% of pts on ICI)



Possible Causes:	Work Up:	Next Steps:
Hypophysitis (1-11%) (N/V, weak, H/A, loss of libido, glucose) Hypothyrojdism New Onset Type 1 DM (1%) Primary AI (RARE!)	Morning Cortisol, ACTH, FSH, LH Cortisol Stimulation Test, consider brain MRI (pituitary protocol) if abnormal TSH/free T4 Glucose, AG, pH, urine/serum ketones, beta-hydroxybutyrate, c-peptide, consider anti-GAD, anti-islet cell	Determine hypophysitis vs primary Al Steroid replacement Levothyroxine Insulin


#### Insomnia/depression/anxiet

У

Exercise, CBT, nutrition

## **Fatality Rates**

#### C Cases and fatality rates





Wang, Jama Onc, 2018


## **Further Research**

- Patient: "What you are doing is going to benefit so many, I will be happy and honored to help in any way possible, to make this journey easier for others, that will make mine even more worthy"
- His Wife: I feel exactly the same, if our journey helps someone elses' be less painful, then it will be even more worthy, if awareness was created then what we endured has more meaning, this is how science advances, this is how we learn, this is how medicine writes the new chapters. I hope God gives me enough years to witness the progresses that I am sure MGH team will achieve. He will remain alive in that progress and one day my kids will have one more reason to be even more proud of their Daddy.



### Short Term - Systems Approaches Applied at Unprecedented Resolution


#### **Building Knowledge Network**




- Biopsy affected tissue(s)

**Collect if patient relapse or develop other irAEs** 

## Next-Generation Microscope: Single Cell Genomics Strategies



## Next-Generation Microscope: Single Cell Genomics Strategies




## **Rapid Autopsy**







# Long term - Survivorship! (Fadden, NP)



MASSACHUSETTS GENERAL HOSPITAL	MELANOMA		
CANCER CENTER	SURVIVORSHIP		
Immu	ne-Mediated Toxicity History		
GI:	Eyes:		
Skin:	Mucosal involvement □ Yes □ No		
Lungs:	Heart:		
Liver:	Kidneys		
Joints/MSK:	Neuro:		
Heme:	Pancreas:		
Infectious Disease:	Allergy:		
	Endocrinopathies		
Primary Hypothyroidism:	Primary Adrenal Insufficiency:		
Type 1 Diabetes Mellitus:	Type 2 Diabetes Mellitus:		
Anterior Hypopituitarism with central/secondary	: 🗆 Hypothyroidism 🛛 Adrenal Insufficiency 🛛 Hypogonadism		
Corticosteroid	History (and Other Immunosuppression)		
Cumulative Corticosteroid Dose (in mg prednisor	ne):		
Still on steroids: □ Yes □ No	Current Daily Dose:		
Other Immunosuppression & Dose/Date(s):			
🗆 Infliximab:	Vedolizumab:		
Hydroxychloroquine:	□ Sulfasalazine:		
□ Mycophenolate Mofetil:	Azathioprine:		
□ Other:			
	Follow Up Care Plan		
Follow Up Testing	Follow up Laboratory Screening		
Bone Mineral Density:	Thyroid:		
Colonoscopy:	Pituitary/Adrenal:		
Skin Exam:	Diabetes:		
Eye Exam:	CBC:		
Echocardiogram:	Liver & Kidneys:		
12-Lead ECG:	Vitamin D:		
Pulmonary Function Tests:	Lipids/BP/Weight:		
Medication:	Prescriber:		

# Let's Answer Our Questions


- How many patients are expected to have a serious immune-related adverse event (irAE) this year in the US alone? (300, 3,000, 10,000, well over 30,000)
- If a patient has one irAE, are they at risk for another? Y/N
- Are all irAE's treated with steroids? Y/N
- Do some irAE's require different doses of steroids? Y/N
- What is the most common organ system involved?
- What are the two most fatal toxicities?



## Next Best Steps

Download the FREE management guidelines

- Haanen, Annals of Oncology, 2017
- Puzanov, Journal of ImmuoTherapy of Cancer, 2017
- Brahmer, Journal of Clinical Oncology, February, 2018
- NCCN Guidelines, May, 2021





## **Thank You**

Patients and Families

- Dr. Daniel Haber, Cancer Center Director
- Dr. Dave Ryan, Chief of Hem Onc, MGH
- Dr. Keith Flaherty, Cancer Center
- Dr. Chloe Villani, CIID, Cancer Center, MGH
- Dr. Steven Blum, MD
- Dr. Amanda Guidon, Neurology, MGH
- Dr. LeeAnn Burton, Neurology, MGH
- Dr. Michael Dougan, GI, MGH
- Dr. Andy Chan, GI, MGH
- Dr. Tom Neilan, Cardiology, MGH
- Dr. Dan Zlotoff, Cardiology, MGH
- Dr. Rebecca Karp, Hematology, MGH
- Dr. Michael Mansour, Infectious Disease, MGH
- Dr. Alyssa Letourneau, Infectious Disease, MGH
- Dr. Alex Faje, Neuroendocrine, MGH
- Dr. Michelle Rengarajan, Endocrine, MGH
- Dr. Minna Kohler, Rheumatology, MGH
- Dr. Sara Schoenfeld, Rheumatology, MGH
- Dr. Mazen Nasrallah, Rheumatology, MGH
- Dr. Molly Thomas, GI, MGH
- Dr. Steven Chen, Dermatology, MGH
- Gabe Molina, Dermatology, MGH
- Dr. Eugene Seminov, Dermatology, MGH
- Dr. Yeku Oladapu, GYN Onc, MGH
- Dr. Xin Gao, GU, MGH
- Dr. Mary Aronow, MEEI/ Ophthalmology
- Dr. Meghan Sise, Renal, MGH
- Dr. Harish Seethapathy, Renal, MGH
- Dr. Ryan Sullivan, Melanoma, MGH Cancer Center



Dr. Justine Cohen, Melanoma, U Penn Dr. Don Lawrence, Melanoma, MGH Cancer Center Dr. Russ Jenkins, Melanoma, MGH Cancer Center Krista Rubin, NP, Melanoma, MGH Cancer Center Riley Fadden, NP, Melanoma, MGH Cancer Center Dr. Howard Kaufman, Melanoma, MGH Cancer Center Dr. Aparna Parikh, GI, MGH Cancer Center Dr. Dejan Juric, Phase I, Rapid Autopsy, MGH Dr. Aditya Bardia, Breast, MGH Cancer Center Dr. Ben Medoff, Pulmonary, MGH Dr. Joey Kong, ITA, MGH Dr. Laura Petrillo, Palliative Care, MGH Dr. Florian Fintelmann, Radiology, MGH Dr. Jong Park, Head and Neck, MGH Dr. Aiden Long, Allergy and Immunology, MGH Dr. Jocelyn Farmer, Allergy and Immunology, MGH Dr. Sara Barmettler, Allergy and Immunology, MGH Dr. Meghan Mooradian, Thoracic Oncology, MGH Dr. Justin Gainor, Thoracic Oncology, MGH Dr. Mari Mino-Knudson, Pathology, MGH Dr. Ruth Foreman, Dermatopathology, MGH Dr. Matthew Frigault, Heme Malignancies, MGH Dr. Leyre Zubiri, Immunotherapy Toxicity Fellow Mike Podolfi, Informatics, Partners ECare Dr. Magid Adawallah, Fellow, Cardiology Dr. Genevieve Boland, Surgical Oncology, MGH Hellen Giang, Clinical Research, MGH Elaina Phan, Clinical Research, MGH Tariq Daouda, Villani Lab Neal Smith, Villani Lab Elizabeth Hockfield Byrne, Villani Lab







A Teaching Affiliate of Harvard Medical School







A Teaching Affiliate of Harvard Medical School

# Case 2



## <u>Case #2</u>

- ID: 65 y/o M with metastatic melanoma
- PMH: prostate cancer (in remission), depression, HL
- Prior treatments: High dose IL-2 and adoptive cell transfer therapy at the NCI. Radiation to brain and spine
  - Treatment Course
    - June 1st: C1D1 on a clinical trial. Combination nivolumab and ipilimumab
    - July 31st: C2D1 reported 2 weeks of non-productive cough, DOE, pleuritic pain, night sweats and increased fatigue
    - Chest CT: "New diffuse bilateral centrilobular groundglass opacity with superimposed areas of peribronchiolar consolidation within the right middle lobe, and peripheral areas of consolidation with central lucency ("reverse halo") concerning for hypersensitivity pneumonitis with organizing pneumonia secondary to drug reaction."


**CANCER CENTER** 

## **Clinical Presentation**

53% Dyspnea35% Cough12% Fever7% Chest pain33% Asymptomatic

Incidence

- PD1/PDL1 3%
- CTLA4 + PD1 10%
- Real World 19%



Naidoo, JCO, 2016 Delauney, Eur Respir J, 2017 Suresh, J Thorac Oncol, 2018



# **Differential Diagnosis**

- Infection/pneumonia
- Disease lymphangitic carcinomatosis, pseudoprogression
- Pulmonary edema
- COPD/bronchioloitis
- Alveolar hemorrhage
- Pleural and pericardial effusions
- And consider.....







Lomax, Int J Rheum Dis, 2017



Work-Up

- It is a diagnosis of exclusion. Need to rule out active infection, worsening metastatic disease, medication induced ILD/IPF, hypersensitivity pneumonitis, CHF.
- Sputum/induced, viral panel, chest CT, bronchoscopy depending on level of suspicion. Decision to bronch is individualized.
- Chest CT, review with experienced radiologist
  - Ground-glass opacities (37%), Cryptogenic-organizing penumonialike (COP-like) (19%), Hypersensitivity type (22%), Interstitial type (7%), Pneumonitis – not otherwise specified (15%)



Naidoo, JCO, 2016

## **Management**

Grade	Naidoo 2017	Delaunay 2017	Definition	Management
	(N = 43)	(N = 64)		
1	40%	1070		Hold drug, repeat chest CT in 4 weeks, if resolved restart drug
2	33%		Symptomatic, involves more than 1 lob or 25-50% of parenchyma	Pred 1 mg/kg, monitor closely, hold drug
3	23%	2070	lung lobes or > 50% lung parenchyma	Hospitalize, IV antibiotics, IV steroids, consider bronch, if no improvement in 48 hours, escalate to grade 4
4	2%	9%		
5	2%	9%		



## **Steroid Refractory Disease**

#### Lack of Evidence Regarding Choice of 2<sup>nd</sup> Line Immunosuppression


Severe (G3–4) <sup>d</sup> ► pneumonitis <sup>a</sup>	<ul> <li>Permanently discontinue immunotherapy<sup>T</sup></li> <li>Inpatient care</li> <li>Infectious workup: <ul> <li>Consider that patient may be immunocompromised</li> <li>Nasal swab for potential viral pathogens</li> <li>Sputum culture, blood culture, and urine culture</li> <li>Pulmonary and infectious disease consultation, consider PFTs</li> <li>Bronchoscopy with BAL to rule out infection and malignant lung infiltration</li> <li>Consider empiric antibiotics if infection has not yet been fully excluded</li> <li>Methylprednisolone 1–2 mg/kg/day. Assess response within 48 hours and plan taper</li> </ul> </li> </ul>
	<ul> <li>Consider adding any of the following if no improvement after 48 hours:         <ul> <li>Infliximab 5 mg/kg IV, a second dose may be repeated 14 days later at the discretion of the treating provider</li> <li>Mycophenolate mofetil 1–1.5g BID then taper in consultation with pulmonary service</li> <li>Intravenous immunoglobulin (IVIG)<sup>i</sup></li> </ul> </li> </ul>

• Ongoing Clinical Trial – PI: Naidoo

Nishino, Clin Cancer Res, 2016 Chipman, J Oncol Pharm Pract, 2017







- Immune Checkpoint Inhibitors Are Now Standard of Care (> 50 indications, in over 15 types of Cancer)
- Success of Single Agent ICI Led To Combination Approvals
- Be Aware Of The Unique "Autoimmune" Toxicity Profile
- irAEs are Typically Grade 1/2 but Severe irAEs Can Be Fatal
- Steroids are a Mainstay of Treatment
- Beware of "fatigue" and "shortness of breath"

Amazon.com, Facing Immunotherapy

